Fig. 3From: Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDAMean (SD) scores for lenvatinib for RR-DTC assigned to each quantitative criterion by the French (a), Italian (b), and Spanish (c) panels versus watchful waiting (1) and sorafenib (2). A constructed, cardinal scoring scale was used, ranging from 0 to 5 for non-comparative and from −5 to 5 for comparative criteriaBack to article page